Skip to contentA
Aclaris Therapeutics, Inc.
A
ACRSAclaris Therapeutics, Inc. Q4 2018 · 10-K
Revenue$3.67M$3.67M+267.3% vs Q4 2017 Net Income-$38.55M-$38.55MN/M vs Q4 2017 EPS Diluted-$0.99-$0.99N/M vs Q4 2017 Gross Profit$160,000−34.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aclaris Therapeutics, Inc. · CIK 1557746 · Engraved from SEC EDGAR
derived
Operating Cash Flowderived-$27,248,000N/M Free Cash Flowderived-$27,394,000N/M Margins · derivedGross margin4.4%−20.2 pt vs Q4 2017
Operating margin-14.0%+724.8 pt vs Q4 2017
Net margin-1050.7%+1245.0 pt vs Q4 2017
ended Dec 31, 2018 · filed Mar 18, 2019 · 77 d after period end